Wyeth

American Cyanamid Company

Wyeth Holdings Corporation

Solvay Pharmaceuticals, B.v.

Pfizer Corporation

American Home Products Corporation

Mahdi Bakir Fawzi

Syed Muzafar Shah

Tianmin Zhu

Richard William Saunders

Eric C Ehrnsperger

Christian Ofslager

Arwinder Singh Nagi

Jonathan Marc Cohen

Kadum A Ali

Sripriya Venkata Ramana Rao

Shailesh Singh

Sumon A Hasan

Hanumantharao Tatapudy

Christopher Richard Diorio

Joseph K Yoon

Panolil C Raveendranath

Horace Fletcher, Iii

Subodh S Deshmukh

Xuejun Tang

George O Morton

Mark Edward Ruppen

Jianxin Gu

Reinhold H Bender

Mahmoud Mirmehrabi

Reinhold H W Bender

Nataliya Bazhina

Wendy Ann Dulin

Gurmukh Chanana

Dominic Ventura

Parimal R Desai

Natalyia Bazhina

Christian Luther Ofslager

Arwinder Nagi

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

Formulations for parenteral delivery of compounds and uses thereof

The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.

Tigecycline compositions and methods of preparation

An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.

Compositions containing piperacillin and tazobactam useful for injection

Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.

Pantoprazole multiparticulate formulations

The present invention provides sustained-release formulations useful and methods for using the same.

Sustained-release formulation and uses thereof

Disclosed herein is a manufacturing process for the preparation of tigecycline suitable for intravenous infusion.

Manufacturing process for tigecycline

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

Serotonin and norepinephrine reuptake inhibitors and uses thereof

Mono- and di-phosphates of 3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile

The present invention provides salt forms, and compositions thereof, useful as modulators of one or more GPCRs and which exhibit desirable characteristics for the same.

Salicylate and gentisate salts of a piperazine compound

Processes are described for preparing 42-pegylated rapamycins including reacting a rapamycin with an acylating agent in the presence of a lipase to form an acylated rapamycin and reacting the acylated rapamycin with a methoxy poly(ethylene glycol) derivative in the presence of a base. Also described are processes for preparing 32-pegylated tacrolimus and/or ascomycin using these steps.

Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants

Growing community of inventors

Morristown, NJ, United States of America

Mahdi Bakir Fawzi